Table I.
Baseline characteristics
| Parameter | Value | |
|---|---|---|
| Age, mean ± SD [years] | 62.7 ±11.2 | |
| Body mass index, mean ± SD [kg/m²] | 28.7 ±4.6 | |
| Male sex, % (n) | 74.1% (43) | |
| P2Y12 inhibitor, % (n) | Clopidogrel | 31.0% (18) |
| Prasugrel | 29.3% (17) | |
| Ticagrelor | 39.7% (23) | |
| Indication for PCI/index event, % (n) | Stable CAD | 27.6% (16) |
| STEMI | 37.9% (22) | |
| NSTEMI | 31.0% (18) | |
| Unstable angina | 3.4% (2) | |
| Concomitant diseases, % (n) | Diabetes mellitus | 31.0% (18) |
| Hypertension | 70.7% (41) | |
| Hyperlipidemia | 56.9% (33) | |
| Current smoking | 32.8% (19) | |
| Concomitant medication, % (n) | (Any) Statin | 82.8% (48) |
| High-dose statin | 67.2% (39) | |
| ARB/ACE inhibitor | 72.4% (42) | |
| β-Blocker | 82.8% (48) | |
| Proton pump inhibitor | 79.3% (46) | |
PCI – percutaneous coronary intervention, CAD – coronary artery disease, STEMI – ST-elevation myocardial infarction, NSTEMI – non-ST-elevation myocardial infarction, ARB – angiotensin receptor blocker, ACE – angiotensin-converting enzyme.